Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Long-term Potentiation01:35

Long-term Potentiation

57.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
57.7K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

977
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
977
Vaccinations01:51

Vaccinations

50.6K
Overview
50.6K
Cancer Vaccines01:30

Cancer Vaccines

860
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
860

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Manufacture of the first FDA-approved batches of 900 kilodalton crystalline type a botulinum toxin for clinical use: a personal remembrance.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Botulinum neurotoxins: A distinct subclass of SNARE-Cleaving endopeptidases.

Anaerobe·2026
Same author

Enteric botulinum neurotoxins facilitate infection by <i>Salmonella</i> and <i>Shigella</i>.

Science advances·2026
Same author

Korean botulinum toxins.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Iatrogenic botulism: a risk for botulinum toxin's medical use?

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Identification and characterization of botulinum neurotoxin-like two-component toxins in <i>Paeniclostridium ghonii</i>.

Science advances·2025

Related Experiment Video

Updated: Dec 12, 2025

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.6K

A Novel High-Potency Tetanus Vaccine.

Amanda Przedpelski1, William H Tepp2, Sabine Pellett2

  • 1Medical College of Wisconsin, Department of Microbiology and Immunology, Milwaukee, Wisconsin, USA.

Mbio
|August 14, 2020
PubMed
Summary

A novel recombinant tetanus vaccine (8MTT) was engineered to be nontoxic and highly immunogenic. This improved tetanus vaccine candidate also serves as a versatile platform for developing new conjugate vaccines.

Keywords:
DNA recombinationEscherichia coliimmune responseimmunizationtetanus toxin

More Related Videos

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

8.9K
Detection and Enrichment of Rare Antigen-specific B Cells for Analysis of Phenotype and Function
09:25

Detection and Enrichment of Rare Antigen-specific B Cells for Analysis of Phenotype and Function

Published on: February 16, 2017

12.7K

Related Experiment Videos

Last Updated: Dec 12, 2025

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.6K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

8.9K
Detection and Enrichment of Rare Antigen-specific B Cells for Analysis of Phenotype and Function
09:25

Detection and Enrichment of Rare Antigen-specific B Cells for Analysis of Phenotype and Function

Published on: February 16, 2017

12.7K

Area of Science:

  • Biotechnology
  • Vaccinology
  • Microbiology

Background:

  • Chemically inactivated tetanus toxoid (CITT) is a widely used but crude vaccine.
  • CITT contains numerous Clostridium tetani proteins, with variable active component percentages.
  • Chemical modification of proteins can alter antigenicity unpredictably.

Purpose of the Study:

  • To engineer a recombinant, genetically inactivated tetanus vaccine.
  • To create a malleable platform for conjugate vaccine development.

Main Methods:

  • Full-length tetanus toxin (TT) was engineered with eight mutations (8MTT) to abolish toxicity.
  • 8MTT was purified and characterized, retaining high amino acid identity to native TT.
  • The immunogenicity and potency of 8MTT were evaluated in outbred mice.

Main Results:

  • 8MTT demonstrated >50 million-fold lower toxicity than native TT.
  • 8MTT vaccination elicited a strong immune response and potent vaccine efficacy against tetanus toxin challenge.
  • Immune response variability was observed among individual mice for both 8MTT and CITT.

Conclusions:

  • 8MTT is a promising candidate for a next-generation tetanus vaccine.
  • 8MTT offers a malleable platform for developing conjugate vaccines against emerging pathogens.